LaurenCSeebergerMD

PubMed

• 1 citations
  Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
  Ying Liu, Jacquelyn Bainbridge, Stefan Sillau, Sarah Rajkovic, Michelle Adkins
  Movement Disorders. 2024-05-01
• 2 citations
  Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease.
  Benzi M Kluger, Maya Katz, Nicholas B Galifianakis, Steven Z Pantilat, Joshua M Hauser
  JAMA Neurology. 2024-01-01
• 1 citations
  Subacute Progressive Imbalance and Jaw Movements Due to Kelch-Like Protein-11 Rhombencephalitis.
  Michael Korsmo, Lauren C Seeberger
  Movement Disorders Clinical Practice. 2022-09-01

Journal Articles

• A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington's Disease  
  Horizon Investigators of the Huntington Study Group and EHDN, JAMA Neurol, 1/1/2013
• Characterization of a Large Group of Individuals with Huntington's disease and Their Relatives Enrolled in the COHORT Study  
  Dorsey ER, the Huntington Study Group Cohort Investigators, PLoS ONE, 1/1/2012
• Activity enhances dopaminergic long duration response in Parkinson's Disease  
  Kang UJ, Auinger P on behalf of the ELLDOPA Investigators, Neurology, 1/1/2012
• Suicidal Ideation in Huntington Disease: The Role of Comorbidity  
  Wetzel HH, Gehl CR, Dellefave-Castillo L, et al, and the Huntington Study Group, Psych Research, 1/1/2011
• Investigation of the Psychometric Properties of the Short Parkinson's Evaluation Scale/ Scales for Outcomes in Parkinson's Disease (SPES/SCOPA)  
  Wilson RE, Seeberger LC, Buck PO, Conner JB, Castelli-Haley J, Value in Health, 1/1/2011
• Examination of the UPDRS Bradykinesia Subscale: Equivalence, Reliability, and Validity  
  Buck PO, Wilson RE, Seeberger LC, Conner JB, Castelli-Haley J, Journal of Parkinson's Disease, 1/1/2011
• Comorbidities of obsessive and compulsive symptoms in Huntington's disease  
  Anderson K, Gehl C, Marder, Beglinger LJ, Paulsen JS and the HSG Study Group, J Nerv Ment Dis, 1/1/2010
• Stalevo (levodopa/carbidopa/entacapone) in Parkinson's disease  
  Seeberger LC, Hauser RA, Expert Review of Neurotherapeutics, 1/1/2009
• Movement Disorders Associated with Aripiprazole Use: A Case Series  
  Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC, International Journal of Neuroscience, 1/1/2009
• Assessment of Dietary Intake Among Adults At Risk for Huntington Disease: Analysis of PHAROS Research Participants  
  Marder K, Hongwei Z, Tanner CM, et al and the Huntington Study Group PHAROS Investigators, Neurology, 1/1/2009
• Long term treatment with Botulinum toxin type A in Cervical Dystonia has low immunogenicity in Mouse Protection Assay  
  Brin MF, Comella CL, Jankovic J, et al. and the CD 017 BoNTA Study Group, Movement Disorders, 1/1/2008
• Randomized controlled trial of ethyl-EPA in Huntington Disease: The TREND HD Study  
  Dorsey ER, Beck CA, Adams M, et al and the Huntington Study Group TREND HD Investigators, Arch Neurol, 1/1/2008
• Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctiations  
  Hauser RA, Shulman LM, Trugman JM, et al and the Istradefylline 6002-US-13 Study Group, Movement Disorders, 1/1/2008
• The mixed lineage kinase inhibitor CEPT-1347 fails to delay disability in early Parkinson's Disease  
  The Parkinson's Study Group PRECEPT investigators, Neurology, 1/1/2007
• Verbal episodic memory declines prior to diagnosis in Huntington's disease  
  Solomon AC, Stout JC, Johnson SA, Langbehn DR, et al., Predict-HD Investigators of the HSG, Neuropsychologia, 1/1/2007
• MS vs HD: Can white matter and subcortical gray matter be distinguished neuropsychologically?  
  Lafosse JM, Corboy JR, Leehey MA, Seeberger LC, Filley CM, J Clinical and Experimental Neuropsychology, 1/1/2007
• Optimizing bioavailability in the treatment of Parkinson's disease  
  Seeberger LC, Hauser RA, Neuropharmacology, 1/1/2007
• At risk for Huntington's disease: the PHAROS cohort enrolled  
  The Huntington Study Group Pharos Investigators, Archives of Neurology, 1/1/2006
• Preparing for preventative clinical trials: the Predict-HD study  
  Paulsen JS, Hayden M, Stout JC, Langbehn DR, et al and the Predict-HD investigators of the HSG, Archives of Neurology, 1/1/2006
• Topiramate in essential tremor: a double-blind, placebo-controlled trial  
  Ondo WG, Jancovic J, Connor GS, et al; Topiramate Essential Tremor Study Investigators, Neurology, 1/1/2006
• Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia  
  Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators, Mov Disord, 1/1/2006
• A randomized, controlled trial of Etilevodopa in Parkinson disease patients with motor fluctuations  
  Parkinson Study Group, Archives of Neurology, 1/1/2006
• Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson disease  
  Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK et al, and the Parkinson Study Group-PROGENI Investigators, Movement Disorders, 1/1/2006
• Long-term safety, efficacy, dosing and development of resistance with botulinum type B in cervical dystonia  
  Berman B, Seeberger LC, Kumar R, Movement Disorders, 1/1/2005
• Efficacy and Safety of Botulinum Type A Toxin (Dysport) in Cervical Dystonia: Results of the First US Randomized, Double-Blind, Placebo-Controlled Study  
  Truong D, Duane D, Jankovic J, Singer C, Seeberger LC, Comella C, Lew M, Rodinitsky R, Danisi F, Sutton J, Charles PD, Hauser R, Shecan G, Movement Disorders, 1/1/2005
• Join now to see all

Books/Book Chapters

• Encyclopedia of Movement Disorders 
  Chapter: Huntington's Disease. 
  Page 39 - 49Seeberger LCEditors: Kompoliti K, Verhagen ML.Academic Press, Oxford2010
• Handbook of Essential Tremor and Other Tremor Disorders 
  Chapter: Cerebellar Tremor. 
  Page 227 - 243Hauser RA, Seeberger LCEditors: Lyons KE, Pahwa R.Taylor and Francis, Boca Raton, FL2005
• Medlink Neurology 
  Chapter: Huntington's Disease. 
  Agarwal P, Seeberger LCEditors: Gilman S, Goldstein GW, Waxman SG.Arbor Publishing, San Diego, CA2004
• Clinical Pain Management: Practical Applications and Procedures Volume 
  Chapter: Botulinum Toxin Injections. 
  Page 277 - 283Seeberger LC, O'Brien CFEditors: Breivik H, Eccleston C.Arnold, Ltd., London, England2002
• Clinical Pain Management: Chronic Pain Volume 
  Chapter: Management of painful Spasticity. 
  Page 459 - 466O'Brien CF, Seeberger LCEditors: Wilson P, Jensen T, Rice A.Arnold, Ltd., London, England2002
• Clinical Evaluation and Management of Spasticity: Current Clinical Neurology Series 
  Chapter: Botulinum Toxin Treatment in Spasticity. 
  Page 173 - 186Seeberger LC, O'Brien CFEditors: Gelber DA, Jeffrey D.Humana Press, NJ2001
• Medlink 
  Chapter: Huntington's Disease. 
  Seeberger LCEditors: Gilman S, Goldstein GW, Waxman SG.Arbor Publishing, San Diego, CA1999
• Caring for the Parkinson's Disease Patient: A Practical Guide 
  Chapter: Sexuality in Parkinson's Disease. 
  Page 122 - 130Seeberger LCEditors: Hutton JT and Dippel RL.Prometheus Books, New York, NY1999
• Neurobase 
  Chapter: Huntington's Disease. 
  Seeberger LCEditors: Gilman S, Goldstein GW, Waxman SG.Arbor Publishing, San Diego, CAEdition 1st,1998
• Handbook of Dystonia 
  Chapter: Phenol Injections in Dystonia. 
  Page 371 - 380Seeberger LCEditors: Stacy MA.
• Join now to see all

Abstracts/Posters

• Ropinirole has a lesser incidence compared to other dopamine agonists of causing compulsive behavior in Parkinson's disease patients.
  Agarwal P, Seeberger LC, Segro V, 10th International Congress of Movement Disorders, Kyoto, Japan, 1/28/2006
• Sudden onset of sleep attacks in a non parkinsonian patient on pramipexole for fibromyalgia.
  Agarwal P, Seeberger LC, Segro V, 10th International Congress of Movement Disorders, Kyoto, Japan, 1/28/2006
• Suicide in a patient with segmental dystonia and successful deep brain stimulation of the globus pallidus internus.
  Agarwal P, Seeberger LC, Segro V, 10th International Congress of Movement Disorders, Kyoto, Japan, 1/28/2006
• Double-blind, randomized study of BOTOX purified neurotoxin complex for treating focal spasticity poststroke.
  Botox Spasticity Study Group, Toxins 2002, Hannover, Germany, 1/1/2002
• Botulinum toxin type B for Limb Spasticity.
  O'Brien CF, Mancini F, Seeberger LC, International Conference Toxins, 1/1/2002
• Persistent Dyskinesia Associated With Serotonin Re-Uptake Inhibitors.
  Seeberger LC, O'Brien CF, Movement Disorders, Vienna, Austria, 1/1/1996
• Primary Postural Tremor in Parkinson's Disease.
  Seeberger LC, Sage JI, Third International Congress of Movement Disorders, Orlando, FL, 1/1/1994
• Idiopathic Cardiomyopathy-a Retrospective Study of Heart Sizes at Autopsy.
  Seeberger LC, Kent S, National Student Research Day and 1986 National FASEB Convention, 1/1/1986
• Join now to see all

Lectures

• "Surgical Interventions in Parkinson's Disease." 
  Boise, ID - 1/16/2014
• "Brass Tacks of Running GCP Compliant Trials." 
  Minneapolis, MN - 1/7/2014
• "Clinical Trials in HD." 
  University of Utah, Salt Lake City, UT - 1/18/2013
• "DBS Treatment for Parkinson's Disease." 
  Boise, ID - 1/19/2012
• "Parkinsonism: Clinical Features and Diagnosis." 
  Sun Valley, ID - 1/1/2011
• "Rural Medicine, Outreach and Research." 
  1/1/2010
• "Parkinson's Disease: Diagnosis and Management." 
  1/1/2010
• "WE MOVE Primidone for Subcortical Myoclonus." 
  1/1/2010
• "NeuroRehabilition National Preceptor Program" 
  1/1/2010
• "Treatment of Non-Motor Features of Parkinson's Disease." 
  University of South Florida, Orlando, FL - 1/24/2009
• "Video Overview of Movement Disorders" 
  Sun Valley, ID - 1/1/2009
• "WE MOVE Drug Induced Movement Disorders" 
  1/30/2008
• "Understanding Parkinson's Disease." 
  Sun Valley, ID - 1/16/2008
• "Diagnosis and Management of Movement Disorders" 
  Sun Valley, ID - 1/16/2008
• Grand Rounds: "Pearls in Treating Parkinson's Disease." 
  ACMEC St. Luke's Regional Medical Center, Boise, ID - 1/10/2008
• "Recognition and Overview of Movement Disorders." 
  St. Luke's Medical Center, Boise, ID - 1/26/2007
• "Non-motor Features of PD with an Intensive Review of Anatomy and Physiology of the Sense of Smell." 
  Portland, OR - 1/16/2007
• "Recognition and Overveiw of Movement Disorders." 
  St. Alphonsus Medical Center, Boise, ID - 1/15/2007
• "Botulinum Toxin Treatment for Neurological Disorders." 
  Tampa, FL - 1/15/2007
• "Non-Motor Manifestations of PD and their Treatment." 
  Savannah, GA - 1/11/2007
• Faculty, "Moving Forward: 2nd Edition A Practical Guide to living with Parkinson's disease." 
  1/1/2007
• "Parkinson's Disease Scientific Advisory Board Meeting" 
  Kansas City, MO - 1/21/2006
• "Basics of Parkinson's disease treatment." 
  Sun Valley, ID - 1/13/2006
• "Overview of Biomarkers in Dystonia." 
  Denver, CO - 1/10/2005
• "Parkinson Disease Diagnosis and Treatment." 
  Vail, CO - 1/6/2005
• Join now to see all

Other

• "WeMove Post-stroke Spasticity Management Initiative" 
  Lauren Seeberger, MD
  1/1/2007
• "Huntington disease." 
  Agarwal P, Seeberger LC, MedLink Neurology
  1/1/2006
• "The role of chemodenervation in Spasticity management." 
  Lauren Seeberger, MD, WeMove Web CME Module
  http://www.mdvu.org/classrooms/cme/spasticity_chemd
  1/1/2005
• "Spasticity: Pathophysiology, Assessment and Management." 
  Lauren Seeberger, MD, WeMove Teaching Slide Set Development
  1/1/2001
• "Huntington's Disease. VanderArk G, editor" 
  Seeberger LC, Colorado Neurological Institute Review, Winter Edition
  Englewood, CO - 1/1/1999
• "Restless Legs Syndrome. VanderArk G, ed." 
  Seeberger LC, Colorado Neurological Institute Review, Spring Edition
  Englewood, CO - 1/1/1999
• Reliability of Measurements of Patient Health Status: A Comparison of Physician, Patient and Caregiver Ratings. 
  McRae C, O'Brien CF, Seeberger LC, and Vo A, Fifth International Congress of Parkinson's Disease and Movement Disorders
  New York City, NY - 1/1/1998
• A New Treatment for Tremor in Multiple Sclerosis. 
  Seeberger LC, Murray R, MS Connection
  1/1/1997
• Join now to see all